ストックスクリーナーアプリを入手
5.85
4.72%
-0.29
前日終値:
$6.14
開ける：
$6.21
24時間の取引高:
5.38M
Relative Volume:
0.64
時価総額：
$2.01B
収益：
-
当期純損益:
$-75.80M
株価収益率:
-16.71
EPS:
-0.35
ネットキャッシュフロー:
$-68.07M
1週間 パフォーマンス:
-27.24%
1か月 パフォーマンス:
-32.45%
6か月 パフォーマンス:
+162.33%
1年 パフォーマンス:
+130.31%
1日の値動き範囲:
$5.8202
$6.25
1週間の範囲:
$5.8202
$7.6998
52週間の値動き範囲:
$1.54
$9.75
Nuvation Bio Inc Stock (NUVB) Company Profile
名前
Nuvation Bio Inc
セクター
電話
(415) 754-3517
住所
357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO
NUVB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NUVB
Nuvation Bio Inc
|
5.85 | 2.10B | 0 | -75.80M | -68.07M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-24 | 開始されました | Truist | Buy |
| 2025-11-19 | 開始されました | B. Riley Securities | Buy |
| 2025-09-30 | 開始されました | Jefferies | Buy |
| 2025-04-23 | 開始されました | Citizens JMP | Mkt Outperform |
| 2024-03-27 | アップグレード | Jefferies | Hold → Buy |
| 2024-03-26 | アップグレード | BTIG Research | Neutral → Buy |
| 2023-01-06 | ダウングレード | Jefferies | Buy → Hold |
| 2022-08-02 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-08-02 | ダウングレード | BTIG Research | Buy → Neutral |
| 2022-05-04 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-15 | 再開されました | BTIG Research | Buy |
| 2021-04-06 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-03-08 | 開始されました | BMO Capital Markets | Outperform |
| 2021-03-08 | 開始されました | BTIG Research | Buy |
| 2021-03-08 | 開始されました | Cowen | Outperform |
| 2021-03-08 | 開始されました | Jefferies | Buy |
| 2021-03-08 | 開始されました | Wedbush | Outperform |
すべてを表示
Nuvation Bio Inc (NUVB) 最新ニュース
Is Nuvation Bio (NUVB) Pricing In Its Sharp Swings Or A Long Runway For Growth - Yahoo Finance
Signal Recap: Should I invest in KORE Group Holdings Inc before earningsJuly 2025 Earnings & Fast Moving Stock Trade Plans - baoquankhu1.vn
A Look At Nuvation Bio (NUVB) Valuation After The Eisai Taletrectinib Licensing Deal - Yahoo Finance
Is Nuvation Bio Inc stock undervalued right nowMarket Growth Report & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Eisai and Nuvation Bio ink licensing deal for taletrectinib - The Pharma Letter
14 Best Booming Stocks to Buy Right Now - Insider Monkey
Nuvation Bio Inc. (NUVB) Announces Exclusive Licensing Agreement With Eisai to Expand Global Reach of Taletrectinib - Insider Monkey
Jones Trading raises Nuvation Bio stock price target to $12 on safusidenib study - Investing.com India
Q1 EPS Estimates for Nuvation Bio Boosted by HC Wainwright - MarketBeat
Nuvation Bio (NUVB) Expands Global Taletrectinib Rights With Eisai Collaboration And Licensing Deal - simplywall.st
Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference - Investing News Network
Asia Deal Watch: Eisai Obtains Rights To Nuvation’s Ibtrozi Outside US, Japan, China - Citeline News & Insights
Nuvation Bio stock price target lowered to $17 at H.C. Wainwright - Investing.com Nigeria
Weekly Earnings: Will Nuvation Bio Inc stock outperform value stocksJobs Report & Free Safe Capital Growth Stock Tips - moha.gov.vn
Down 24% in 4 Weeks, Here's Why Nuvation Bio (NUVB) Looks Ripe for a Turnaround - Yahoo Finance
Nuvation Bio stock rating reiterated at Market Outperform by Citizens - Investing.com Nigeria
Nuvation Bio and Eisai license Taletrectinib rights outside US, China and Japan for $230 M - BioSpectrum Asia
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan - Quamnet
Nuvation Bio Faces Challenges Amidst Financial and Market Turbulence - StocksToTrade
Nuvation Bio stock slides nearly 18% as Eisai deal, early IBTROZI sales hit screens - TechStock²
NUVB Stock Dips Amidst Market Uncertainty and Strategic Pressure - StocksToTrade
Expert Outlook: Nuvation Bio Through The Eyes Of 9 Analysts - Benzinga
NUVB Stock Surges Following Promising Expansion News - timothysykes.com
Nuvation Bio (NYSE:NUVB) Shares Gap Down After Analyst Downgrade - MarketBeat
HC Wainwright Has Lowered Expectations for Nuvation Bio (NYSE:NUVB) Stock Price - MarketBeat
Nuvation Bio (NUVB): HC Wainwright & Co. Lowers Price Target, Ma - GuruFocus
Nuvation Bio Expands Global Reach with Eisai Partnership - TipRanks
Nuvation Bio Reports Preliminary Fourth Quarter And Full Year 2025 Financial Results And Provides 2026 Outlook Ahead Of 44Th Annual J.P. Morgan Healthcare Conference - TradingView — Track All Markets
Nuvation Bio Signs License and Collaboration Agreement With Eisai - TradingView — Track All Markets
Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan - The AI Journal
Nuvation Bio and Eisai enter into exclusive licensing agreement for taletrectinib in Europe and additional countries outside U.S., China and Japan - marketscreener.com
Wall Street Analysts Believe Nuvation Bio (NUVB) Could Rally 25.14%: Here's is How to Trade - MSN
Why Nuvation Bio Inc. Warrants stock gets analyst attentionWeekly Stock Recap & Fast Gain Swing Trade Alerts - Улправда
Hennion & Walsh Asset Management Inc. Has $1.26 Million Stock Holdings in Nuvation Bio Inc. $NUVB - MarketBeat
Moving Averages: How Nuvation Bio Inc stock reacts to bond yieldsVolume Spike & Long-Term Investment Growth Plans - moha.gov.vn
Nuvation Bio stock falls as UBS starts coverage; NUVB investors eye JPM conference next week - TechStock²
A Look At Nuvation Bio (NUVB) Valuation After The Recent UBS Downgrade - Sahm
Nuvation Bio Inc. (NUVB) Stock Analysis: 32.81% Potential Upside Sparks Investor Interest - DirectorsTalk Interviews
Is Nuvation Bio Inc. stock positioned for long term growth2025 Major Catalysts & Technical Pattern Recognition Alerts - ulpravda.ru
How Nuvation Bio Inc. stock reacts to oil pricesPortfolio Gains Report & Consistent Profit Alerts - ulpravda.ru
How Nuvation Bio Inc. stock reacts to bond yieldsJuly 2025 Momentum & Low Drawdown Investment Ideas - ulpravda.ru
Is Nuvation Bio Inc. stock safe for conservative investorsMarket Risk Report & Daily Momentum Trading Reports - ulpravda.ru
Why Nuvation Bio Inc. Class stock remains stableJuly 2025 Earnings & Safe Investment Capital Preservation Plans - ulpravda.ru
Why Nuvation Bio Inc. stock is trending among retail tradersWeekly Trade Summary & Weekly Chart Analysis and Guides - ulpravda.ru
Aug Swings: Why Nuvation Bio Inc. stock is trending among retail traders2025 Price Targets & Long-Term Growth Portfolio Plans - ulpravda.ru
How Nuvation Bio Inc. stock reacts to global recession fears2025 Short Interest & Step-by-Step Swing Trade Plans - ulpravda.ru
RBC Raises Price Target on Nuvation Bio to $9 From $8, Keeps Outperform, Speculative Risk - MarketScreener
UBS Initiates Coverage of Nuvation Bio (NUVB) with Neutral Recommendation - Nasdaq
Nuvation Bio Inc.'s (NYSE:NUVB) institutional investors lost 5.2% last week but have benefitted from longer-term gains - Yahoo Finance
UBS initiates Nuvation Bio stock with Neutral rating, $10 price target - Investing.com
Nuvation Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference - BioSpace
Nuvation Bio Inc (NUVB) 財務データ
収益
当期純利益
現金流量
EPS
4.73%
0.92%
大文字化:
|
ボリューム (24 時間):